Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.
Acknowledgements
M.P. and C.N. are supported by the County of Salzburg and FP7-PIRSES- GA-2008-230661 or PMU-FFF-E-12/15/075.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (box)
Further regulatory documents related to personalized medicine (PDF 61 kb)
Rights and permissions
About this article
Cite this article
Nofziger, C., Papaluca, M., Terzic, A. et al. Policies to aid the adoption of personalized medicine. Nat Rev Drug Discov 13, 159–160 (2014). https://doi.org/10.1038/nrd4257
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4257
- Springer Nature Limited
This article is cited by
-
Blood glutamine synthetase signaling in alcohol use disorder and racial disparity
Translational Psychiatry (2022)
-
Pharmacogenomic information in drug labels: European Medicines Agency perspective
The Pharmacogenomics Journal (2015)